APA (7th ed.) Citation

Bafaloukos, D., Linardou, H., Aravantinos, G., Papadimitriou, C., Bamias, A., Fountzilas, G., . . . Dimopoulos, A. M. (2010). A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: A Hellenic Cooperative Oncology Group study. BMC Medicine, 8, 1. https://doi.org/10.1186/1741-7015-8-3

Chicago Style (17th ed.) Citation

Bafaloukos, Dimitrios, et al. "A Randomized Phase II Study of Carboplatin Plus Pegylated Liposomal Doxorubicin Versus Carboplatin Plus Paclitaxel in Platinum Sensitive Ovarian Cancer Patients: A Hellenic Cooperative Oncology Group Study." BMC Medicine 8 (2010): 1. https://doi.org/10.1186/1741-7015-8-3.

MLA (9th ed.) Citation

Bafaloukos, Dimitrios, et al. "A Randomized Phase II Study of Carboplatin Plus Pegylated Liposomal Doxorubicin Versus Carboplatin Plus Paclitaxel in Platinum Sensitive Ovarian Cancer Patients: A Hellenic Cooperative Oncology Group Study." BMC Medicine, vol. 8, 2010, p. 1, https://doi.org/10.1186/1741-7015-8-3.